News
Entasis Therapeutics Introduces ETX0462, a First-in-Class Candidate, Targeting Multidrug-Resistant Gram-Negative and Biothreat Pathogens Entasis Therapeutics Holdings Inc. Thu, Jul 1, 2021, 8:00 ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback